Here we identify that drug-resistant BTK mutations occur in distinct enzymatic classes, some of which render BTK enzymatically impaired while conferring novel protein-protein interactions to sustain B-cell receptor (BCR) signaling.
ORGANISM(S): Homo sapiens (Human)
